Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ibrutinib Post-Allogeneic HCT for Lymphoma
NCT02869633Phase 2Completed
- Sponsor
- Vanderbilt-Ingram Cancer Center
- Start
- Nov 2016
- Primary completion
- Nov 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of ibrutinib in lymphoma, chronic lymphocytic leukemia (CLL), Hodgkin lymphoma (HL), mantle cell lymphoma (MCL), follicular lymphoma (FL), sponsored by Vanderbilt-Ingram Cancer Center. Started Nov 2016; status: completed.
02
Drugs
ibrutinib
03
Conditions
lymphomachronic lymphocytic leukemia (CLL)Hodgkin lymphoma (HL)mantle cell lymphoma (MCL)follicular lymphoma (FL)
Beyond the preview
Go deeper on NCT02869633.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02869633.